With the 2016 election of Donald Trump, some healthcare industry experts predicted a substantially relaxed enforcement environment. Fatigued by burdensome regulation under the Obama Administration, many welcomed change. However, now that Trump’s first year has come to a close, it is clear that the fight against healthcare fraud has not completely fallen by the wayside. We may one day look back and conclude that enforcement under the current administration was indeed less aggressive; still, the level of activity in the administration’s first year underscores that boards of directors of healthcare organizations must remain vigilant in their compliance efforts to ensure that the organizations they serve do not end up in the government’s crosshairs.

In their recent article for the Cleveland Metropolitan Bar Journal, Jayne Juvan and Kelli Novak examine the fiduciary duties applicable to boards of directors of health care organizations and examine key health care regulatory risk areas that boards should be aware of in 2018. The article is available here.